Monkey virus in humans may trigger cancer: experts
Last Updated: 2002-07-12 10:01:08 -0400 (Reuters
Health)
By Alicia Ault
WASHINGTON (Reuters Health) - Though there is still no clear
consensus, a majority of researchers told a quasi-governmental health panel
Thursday that simian virus 40 (SV40) has become established in humans, and that
it plays a role in causing cancer, including in people who had
virus-contaminated polio vaccines in the 1950s and 1960s.
The experts addressed the Institute of Medicine's (IOM) Immunization Safety
Committee, which met to hear the latest epidemiologic and lab data on SV40. In 2
to 3 months, the committee will issue a report, along with recommendations based
on their assessment of the data.
SV40's role in cancer has been debated since the early 1960s, when it was
discovered that inactivated polio vaccine contained the naturally occurring
monkey virus. Monkey kidney cells were fingered as the source; they were used to
grow polio for the shot. In 1961, scientists discovered SV40 caused cancer in
rodents. The government required all future polio vaccine to be SV40-free.
Even so, some contaminated vaccine still on shelves may have been used, and
as many as 98 million children had already been exposed during the government's
Mass Immunization Program from 1955 until early 1963.
Several attorneys alleged that the three polio vaccine makers--Wyeth, Lederle
and Pfizer--knowingly distributed contaminated products before 1961 and later.
Stan Kops, an attorney who successfully sued those companies for causing polio
in vaccinees, alleged at the meeting that Lederle continued to sell SV40-tainted
oral polio vaccine until 1999.
Attorney Donald MacLachlan, representing five families who claim the vaccine
caused cancer, told Reuters Health that a federal judge in Los Angeles recently
allowed a case against Wyeth to proceed.
Scientists have tried to unravel whether SV40 is prevalent in humans, and if
the polio vaccine caused infection, or if SV40 had been in humans previously. In
the 1970s, SV40 was isolated in human tumors, especially brain and bone cancers,
and, more recently, in mesotheliomas, a rare
lung cancer found mostly in people over age 50, and primarily in men with
occupational exposure to asbestos.
Michele Carbone of Loyola University in Chicago, Illinois has linked SV40 to
mesothelioma. He called SV40 a "potent human carcinogen," capable of
transforming cells and inhibiting the p53 gene that normally keeps cancer cells
in check. But he added that the virus is not likely to act alone, and that
co-factors--like asbestos--lead to cancer.
In 2002, several researchers found SV40 in
non-Hodgkin's lymphoma (NHL). Janet Butel, a Baylor College of Medicine
virologist, isolated SV40 in NHL and has sequenced SV40 genomes. In three NHL
samples, the SV40 strain was the same as one found in samples of a polio vaccine
used in the 1950s, she said. SV40 "seems to be established in humans," and "it
is causing infection," said Butel.
"Perhaps it was there before the polio vaccine, I don't know," she said,
adding that widespread vaccine use may have broadly distributed SV40 in humans.
The virus has been found in many nations.
Erik Engels of the National Cancer Institute is conducting a study in
northern India, where monkeys and humans live in close proximity, to see if--and
how--SV40 might be jumping species or being transmitted from human-to-human.
Another researcher, Jeffrey Kopp of the National Institute of Diabetic,
Digestive and Kidney Diseases, said a small study he and colleagues recently
completed found SV40 in blood and urine of both healthy people and kidney
disease patients, and that "argues for relatively common infection in the
general population." Kopp's study will be published in September's Journal of
the American Society of Nephrology.
There were several nay-sayers, including long-time SV40 researcher Keerti
Shah of Johns Hopkins University Bloomberg School of Public Health. Shah has
been unable to isolate SV40 in human urine, and said that lab studies have been
so inconsistent that they do not prove causality.
Howard Strickler, an epidemiologist at the Albert Einstein College of
Medicine in New York, presented several studies he has conducted, all showing no
association between SV40 and cancer incidence, he said.
In a 1998 study in The Journal of the American Medical Association, Strickler
and colleagues found no link between SV40 exposure and a type of cancer called
ependymoma. Strickler also analyzed mesothelioma rates and said that incidence
has remained at a steady 3% a year. It is very rare and not rising in women,
said Strickler, which he said argued against the possibility that the cancer is
being driven by polio vaccine exposure.
Also, rates have only increased among people over 50, who were least likely
to have been vaccinated, he said.
That was disputed by Carbone, who said a large number of people aged 20 to 45
were vaccinated in the 1960s, and that age group is having more mesothelioma.
Susan Fisher, chief of the division of epidemiology at the University of
Rochester, conducted a cohort study, comparing people born between 1955-1959 who
were likely exposed to vaccine to those born between 1961-1965, and documented
cancer incidence in that group from 1973 to 1993.
In the vaccine-exposed group, there was a 178% increase in mesothelioma, and
an increased incidence of ependymoma and osteosarcoma. But, because the cancers
are rare, the differences between the exposed and unexposed group were not
statistically significant, said Fisher.
Copyright © 2002 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content, including by framing or
similar means, is expressly prohibited without the prior written consent of
Reuters. Reuters shall not be liable for any errors or delays in the content, or
for any actions taken in reliance thereon. Reuters and the Reuters sphere logo
are registered trademarks and trademarks of the Reuters group of companies
around the world.